Despite elafibranor failing, obeticholic acid not securing FDA approval and COVID-19 related limitations in the conduct of clinical trials, “this was a very good year actually for NASH clinical trials,” with “some significant advances in terms of therapeutics for NASH” and . We had the results of several trials this year. We had the unfolding story of other molecules that are in development for NASH and all this makes for a very, very vibrant environment in terms of therapeutic research for NASH.” Further, MRI-based methods “are becoming mainstream,” starting to fulfill the promise of non-invasive testing.
